Edition:
United States

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

4.20USD
24 Nov 2017
Change (% chg)

$0.05 (+1.20%)
Prev Close
$4.15
Open
$4.20
Day's High
$4.22
Day's Low
$4.10
Volume
12,422
Avg. Vol
61,100
52-wk High
$5.67
52-wk Low
$2.40

Chart for

About

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from... (more)

Overall

Beta: 1.57
Market Cap(Mil.): $173.00
Shares Outstanding(Mil.): 41.69
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.97 15.54
EPS (TTM): -- -- --
ROI: -- -10.87 11.80
ROE: -- -36.85 15.75

BRIEF-Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy

* Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy

Aug 16 2017

BRIEF-Fate Therapeutics Q2 ‍net loss per common share $0.23​

* Fate Therapeutics reports second quarter 2017 financial results

Aug 14 2017

BRIEF-Fate Therapeutics to amend and restate loan and security agreement

* Fate Therapeutics Inc - on July 14, 2017 co entered into first amendment to amended and restated loan and security agreement - SEC filing

Jul 14 2017

Earnings vs. Estimates